Journal
JOURNAL OF INTERNAL MEDICINE
Volume 264, Issue 4, Pages 295-314Publisher
WILEY
DOI: 10.1111/j.1365-2796.2008.02015.x
Keywords
coronary heart disease; C-reactive protein
Categories
Funding
- Medical Research Council [7900510]
- National Heart Lung and Blood Institute of the US NIH [1 R01 HL078578-01]
- Pentraxin Therapeutics Ltd
- British Heart Foundation [FS/05/125]
- Rosetrees Trust
- Wellcome Trust
- BUPA Foundation
- GlaxoSmithKline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078578] Funding Source: NIH RePORTER
- British Heart Foundation [RG/08/014/24067] Funding Source: researchfish
- Medical Research Council [G7900510] Funding Source: researchfish
- MRC [G7900510] Funding Source: UKRI
Ask authors/readers for more resources
Modestly elevated baseline concentrations of C-reactive protein (CRP), the classical acute phase protein, are associated with the long-term risk of coronary heart disease in general populations, whilst the major acute phase response of CRP following myocardial infarction is associated with death and cardiac complications. The pathogenic and clinical significance of these associations is controversial. Here we critically review the evidence and describe large-scale epidemiological studies, novel experiments and possible specific therapies which will rigorously inform the debate. We distinguish between the potential pathogenicity of high acute phase circulating CRP concentrations in individuals with substantial tissue damage and modest but persistent increases in baseline values in generally healthy subjects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available